Trastuzumab Biosimilar – Anti-HER2 mAb ADC – Research Grade – vc MMAE

Description of Trastuzumab Biosimilar - Anti-HER2 mAb ADC - Research Grade - vc MMAE

PX-TA1005-MMAEd4-1MG is a trastuzumab biosimilar developed by ProteoGenix for research-grade applications in antibody-drug conjugate (ADC) development. This monoclonal antibody mirrors the structure and binding characteristics of trastuzumab (anti-HER2 mAb), making it suitable for comparative studies and early-stage screening in oncology research.

The antibody is conjugated to Monomethyl Auristatin E (MMAE), a potent microtubule-disrupting agent, via a cleavable valine-citrulline-p-aminobenzyl carbamate (c-ValCitPAB) linker. This linker system is enzymatically cleaved in lysosomal environments, allowing for controlled intracellular drug release. The conjugation yields a consistent Drug-to-Antibody Ratio (DAR) of 4, optimized for biological activity while maintaining stability.

PX-TA1005-MMAEd4-1MG is not intended for therapeutic use but serves as a robust research tool for:

• Evaluating the cytotoxic potency of MMAE in HER2-positive cell lines
• Modeling ADC performance in vitro and in vivo using a clinically validated antibody scaffold
• Studying payload delivery, internalization, and bystander effects
• Supporting pharmacokinetic and stability assays during ADC formulation

As a biosimilar to trastuzumab, PX-TA1005 enables researchers to explore HER2-targeted strategies without the cost or restrictions associated with commercial antibodies. Its defined DAR and validated linker-payload system make it an ideal candidate for early-phase ADC feasibility and screening studies.

Manufactured under strict quality controls, PX-TA1005-MMAEd4-1MG provides consistent, reproducible results for scientists working in oncology, therapeutic antibody engineering, and ADC research.